IL163562A0 - fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient - Google Patents
fused pyridazine derivative compounds and drugs containing the compounds as the active ingredientInfo
- Publication number
- IL163562A0 IL163562A0 IL16356203A IL16356203A IL163562A0 IL 163562 A0 IL163562 A0 IL 163562A0 IL 16356203 A IL16356203 A IL 16356203A IL 16356203 A IL16356203 A IL 16356203A IL 163562 A0 IL163562 A0 IL 163562A0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- useful
- formula
- diseases
- active ingredient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002042259 | 2002-02-19 | ||
JP2002199673 | 2002-07-09 | ||
PCT/JP2003/001694 WO2003070707A1 (fr) | 2002-02-19 | 2003-02-18 | Composes condenses derives de la pyridazine et medicaments contenant lesdits composes comme ingredients actifs |
Publications (1)
Publication Number | Publication Date |
---|---|
IL163562A0 true IL163562A0 (en) | 2005-12-18 |
Family
ID=27759644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16356203A IL163562A0 (en) | 2002-02-19 | 2003-02-18 | fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
Country Status (18)
Country | Link |
---|---|
US (2) | US7402580B2 (fr) |
EP (2) | EP2281818A1 (fr) |
JP (2) | JP3843454B2 (fr) |
KR (1) | KR100663147B1 (fr) |
CN (1) | CN100348587C (fr) |
AT (1) | ATE507207T1 (fr) |
AU (1) | AU2003211381B9 (fr) |
BR (1) | BR0307780A (fr) |
CA (1) | CA2476406A1 (fr) |
DE (1) | DE60336890D1 (fr) |
IL (1) | IL163562A0 (fr) |
MX (1) | MXPA04008014A (fr) |
NO (1) | NO328053B1 (fr) |
NZ (1) | NZ534712A (fr) |
PL (1) | PL372171A1 (fr) |
RU (1) | RU2292337C2 (fr) |
TW (1) | TW200306836A (fr) |
WO (1) | WO2003070707A1 (fr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
AU2003229953A1 (en) | 2002-04-30 | 2003-11-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
DK1684736T3 (da) | 2003-12-01 | 2011-11-21 | Kudos Pharm Ltd | Inhibitorer af DNA-skadereparation til behandling af cancer |
PE20060285A1 (es) * | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
KR20070057859A (ko) * | 2004-08-26 | 2007-06-07 | 쿠도스 파마슈티칼스 리미티드 | 4-헤테로아릴메틸 치환된 프탈라지논 유도체 |
GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
DE102005011822A1 (de) * | 2005-03-15 | 2006-09-21 | Merck Patent Gmbh | Phthalazinone |
US20090226412A1 (en) | 2005-06-24 | 2009-09-10 | Ono Pharmaceutical Co., Ltd., | Agent for reduction of bleeding in cerebrovascular disorder |
JPWO2007026771A1 (ja) * | 2005-08-31 | 2009-03-12 | 小野薬品工業株式会社 | 点滴用注射剤 |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
CA2652167A1 (fr) * | 2006-05-31 | 2007-12-06 | Philip Jones | Derives de pyrrolo[1,2-a]pyrazin-1(2h)-one et de pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one utilises en tant qu'inhibiteurs de la poly(adp-ribose)polymerase (parp) |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
US8466150B2 (en) * | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
PL2120579T3 (pl) * | 2006-12-28 | 2014-04-30 | Abbvie Inc | Inhibitory polimerazy poli(ADP-rybozy) |
TW200901974A (en) * | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
JP2010540440A (ja) | 2007-09-21 | 2010-12-24 | エピファニー バイオサイエンシズ, インク. | バロマシクロビル多形体 |
CN101821242B (zh) | 2007-10-17 | 2013-07-24 | 库多斯药物有限公司 | 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮 |
UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
US8455488B2 (en) * | 2008-06-06 | 2013-06-04 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
PT2292231E (pt) * | 2008-06-23 | 2015-12-31 | Nippon Shinyaku Co Ltd | Agente terapêutico para a estenose do canal espinal |
US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
ES2466565T3 (es) | 2008-08-06 | 2014-06-10 | Biomarin Pharmaceutical Inc. | Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
LT2346495T (lt) | 2008-10-07 | 2016-10-10 | Astrazeneca Uk Limited | Farmacinė kompozicija 514 |
DE102009007075B4 (de) * | 2009-02-02 | 2011-05-26 | Siemens Aktiengesellschaft | Workflow-abhängiges Erstellen einer Patienten-CD |
WO2011058367A2 (fr) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase |
CN102108078B (zh) * | 2009-12-24 | 2013-10-30 | 沈阳药科大学 | 1,4-取代酞嗪类化合物及其制备方法和用途 |
EP2531033A4 (fr) | 2010-02-03 | 2013-07-31 | Biomarin Pharm Inc | Inhibiteurs à base de dihydropyridophtalazinone de la poly(adp-ribose) polymérase (parp) utilisables dans le cadre du traitement de maladies associées à un déficit en pten |
SI2533640T1 (sl) | 2010-02-08 | 2017-02-28 | Medivation Technologies, Inc. | Postopki sinteze derivatov dihidropiridoftalazinona |
CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
PL2620436T3 (pl) * | 2010-09-24 | 2018-10-31 | Shionogi & Co., Ltd. | Prolek podstawionej policyklicznej pochodnej karbamoilopirydonowej |
KR20180069132A (ko) * | 2010-10-21 | 2018-06-22 | 메디베이션 테크놀로지즈 엘엘씨 | 결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염 |
EP3925962A1 (fr) | 2011-05-31 | 2021-12-22 | Rakovina Therapeutics Inc. | Inhibiteurs tricycliques de poly(adp-ribose)polymérase |
EP2731951B1 (fr) | 2011-07-13 | 2015-08-19 | Novartis AG | Composés de 4-oxo-3,5,7,8-tétrahydro-4h-pyrano{4,3-d}pyriminidinyle utilisables à titre d'inhibiteurs de tankyrases |
CN103781776A (zh) | 2011-07-13 | 2014-05-07 | 诺华股份有限公司 | 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物 |
WO2013008217A1 (fr) | 2011-07-13 | 2013-01-17 | Novartis Ag | Composés de 4-pipéridinyle utiles comme inhibiteurs de la tankyrase |
TWI596095B (zh) * | 2013-03-13 | 2017-08-21 | 中外製藥股份有限公司 | Dihydropyridazine-3,5-dione derivatives |
US9394299B2 (en) | 2013-09-05 | 2016-07-19 | Warner Babcock Institute For Green Chemistry, Llc | Rilyazine derivatives and compositions for the treatment of cancer |
RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
LT4219508T (lt) * | 2015-04-28 | 2024-08-26 | Shionogi & Co., Ltd | Pakeistas policiklinis piridono darinys ir jo provaistas |
CN105646497B (zh) * | 2016-02-01 | 2019-06-04 | 南京格亚医药科技有限公司 | 吡咯并三嗪酮衍生物 |
EP3615026B1 (fr) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | Un inhibiteur de parp en combinaison avec un glucocorticoïde et/ou de l'acide ascorbique et/ou un facteur de croissance de protéines pour traiter des troubles de la cicatrisation de plaies |
GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
WO2021108350A1 (fr) | 2019-11-25 | 2021-06-03 | The Research Foundation For The State University Of New York | Polythérapie utilisant des inhibiteurs de fabp5 avec des taxanes pour le traitement du cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (fr) | 1956-03-21 | 1900-01-01 | ||
US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
DE3302021A1 (de) | 1983-01-22 | 1984-07-26 | Basf Ag, 6700 Ludwigshafen | 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung |
FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
PT971901E (pt) | 1997-01-15 | 2003-07-31 | Altana Pharma Ag | Ftalazinonas |
US6677333B1 (en) | 1999-01-26 | 2004-01-13 | Ono Pharmaceutical Co., Ltd. | 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient |
AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
-
2003
- 2003-02-18 JP JP2003569614A patent/JP3843454B2/ja not_active Expired - Fee Related
- 2003-02-18 AT AT03705265T patent/ATE507207T1/de not_active IP Right Cessation
- 2003-02-18 CN CNB038084597A patent/CN100348587C/zh not_active Expired - Fee Related
- 2003-02-18 EP EP10178316A patent/EP2281818A1/fr not_active Withdrawn
- 2003-02-18 US US10/505,012 patent/US7402580B2/en not_active Expired - Fee Related
- 2003-02-18 AU AU2003211381A patent/AU2003211381B9/en not_active Ceased
- 2003-02-18 DE DE60336890T patent/DE60336890D1/de not_active Expired - Lifetime
- 2003-02-18 EP EP03705265A patent/EP1477175B1/fr not_active Expired - Lifetime
- 2003-02-18 PL PL03372171A patent/PL372171A1/xx not_active Application Discontinuation
- 2003-02-18 KR KR1020047012806A patent/KR100663147B1/ko not_active IP Right Cessation
- 2003-02-18 WO PCT/JP2003/001694 patent/WO2003070707A1/fr active Application Filing
- 2003-02-18 RU RU2004127932/04A patent/RU2292337C2/ru not_active IP Right Cessation
- 2003-02-18 NZ NZ534712A patent/NZ534712A/en not_active IP Right Cessation
- 2003-02-18 CA CA002476406A patent/CA2476406A1/fr not_active Abandoned
- 2003-02-18 BR BR0307780-2A patent/BR0307780A/pt not_active IP Right Cessation
- 2003-02-18 IL IL16356203A patent/IL163562A0/xx unknown
- 2003-02-18 MX MXPA04008014A patent/MXPA04008014A/es active IP Right Grant
- 2003-02-19 TW TW092103373A patent/TW200306836A/zh unknown
-
2004
- 2004-08-17 NO NO20043429A patent/NO328053B1/no not_active IP Right Cessation
-
2008
- 2008-06-11 US US12/137,267 patent/US20080261947A1/en not_active Abandoned
-
2010
- 2010-05-20 JP JP2010115956A patent/JP2010209106A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1477175B1 (fr) | 2011-04-27 |
WO2003070707A1 (fr) | 2003-08-28 |
EP2281818A1 (fr) | 2011-02-09 |
CN100348587C (zh) | 2007-11-14 |
KR100663147B1 (ko) | 2007-02-28 |
RU2004127932A (ru) | 2005-05-27 |
ATE507207T1 (de) | 2011-05-15 |
AU2003211381B2 (en) | 2009-03-05 |
TW200306836A (en) | 2003-12-01 |
RU2292337C2 (ru) | 2007-01-27 |
EP1477175A4 (fr) | 2006-03-22 |
NZ534712A (en) | 2006-11-30 |
DE60336890D1 (de) | 2011-06-09 |
US20050085476A1 (en) | 2005-04-21 |
AU2003211381B9 (en) | 2009-07-30 |
CA2476406A1 (fr) | 2003-08-28 |
NO328053B1 (no) | 2009-11-16 |
JPWO2003070707A1 (ja) | 2005-06-09 |
JP2010209106A (ja) | 2010-09-24 |
MXPA04008014A (es) | 2004-11-26 |
NO20043429L (no) | 2004-11-19 |
US20080261947A1 (en) | 2008-10-23 |
EP1477175A1 (fr) | 2004-11-17 |
AU2003211381A1 (en) | 2003-09-09 |
KR20040085199A (ko) | 2004-10-07 |
CN1646499A (zh) | 2005-07-27 |
JP3843454B2 (ja) | 2006-11-08 |
PL372171A1 (en) | 2005-07-11 |
US7402580B2 (en) | 2008-07-22 |
BR0307780A (pt) | 2004-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL163562A0 (en) | fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | |
EP1148053A4 (fr) | Derives 2h-phthalazine-1-one et medicaments renfermant ces derives comme principe actif | |
AU2001273574A1 (en) | Substituted 5-alkynyl pyrimidines having neurotrophic activity | |
TR199801367A2 (xx) | 5H- tiazol (3,2-a) pirimidin t�revleri | |
DE69912808D1 (de) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel | |
DE60017279D1 (en) | Pyrimidinderivate | |
HUP0401849A2 (hu) | Kinuklidinszármazékok, ezeket tartalmazó gyógyászati készítmények, továbbá ezek alkalmazása M2 és/vagy M3 muszkarin receptor inhibitorként | |
TWI255817B (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | |
CA2501799A1 (fr) | Composes pyrazole pour le traitement de maladies neurodegeneratives | |
TW200624431A (en) | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents | |
EP1609798A4 (fr) | Derive heterocyclique fusionne, composition medicale le contenant et utilisation medicale associee | |
EP1477489A4 (fr) | Derives de pyrrolopyrimidine | |
CY1105507T1 (el) | Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες | |
CA2468649A1 (fr) | Antagonistes du recepteur a2a d'adenosine | |
HUP0401210A2 (hu) | NK-1 receptor antagonisták felhasználása agy-, gerinc- vagy idegsérülések kezelésére alkalmas gyógyászati készítmények előállítására | |
WO2000003997A1 (fr) | Derives de thiobenzimidazole | |
WO2003048164A3 (fr) | Antagonistes du recepteur a2a de l'adenosine | |
IL197235A (en) | Medical and product preparations containing ingredients that have pde5 inhibitor properties and their use in the manufacture of drugs | |
WO2020263980A8 (fr) | Dérivés d'imidazo[1,2-a]pyridinyle et leur utilisation dans le traitement d'une maladie | |
WO2004048328A3 (fr) | N-arylsulfonyl-3-aminoalkoxyindoles | |
WO2004041802A8 (fr) | Derives de 4(phenyl-piperazinyl-methyl) benzamide et utilisation de ceux-ci pour le traitement de la douleur et des troubles gastro-intestinaux | |
Fish et al. | 4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia | |
EP1254898A4 (fr) | Derives heterocycliques condenses au benzene et medicaments contenant ceux-ci comme ingredients actifs | |
IL92233A0 (en) | 1,2,3,4-tetrahydro-1,9-acridinediamines,a process for their preparation and their use as pharmaceutical compositions | |
Singhi et al. | Extrapyrbmidal syndrome following chloroquine therapy |